Since ErbB3 is sometimes regarded as “undruggable’ due to its lack of phosho-activity,47 allosteric inhibitors were recently developed to prevent ErbB3 from dimer signaling.48 In another study, bi-specific antibody for IGF1R and ErbB3 was tested in preclinical models of pancreatic cancer.49 Further investigation is currently underway in our lab to investigate ErbB3’s role in LMD. This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.